Drug-resistant tuberculosis: a priority pathogen for enhanced public health research and practice
- 11 December 2025
- journal article
- review article
- Published by American Society for Microbiology in Clinical Microbiology Reviews
- Vol. 38 (4) , e0006425
Abstract
SUMMARY: Drug-resistant tuberculosis (DR-TB) causes substantial morbidity and mortality and has hindered progress toward TB elimination. This slowed progress toward the WHO End TB Strategy’s targets was exacerbated by lower TB detection during the COVID-19 pandemic. To inform research and development priorities, we conducted a narrative review of global DR-TB epidemiology and strategies for DR-TB prevention, diagnostics, and treatment. Gaps remain in DR-TB diagnosis, TB drug susceptibility testing (DST), and treatment. The review also shows that DR-TB causes significant post-disease disability, particularly chronic lung disease, impacting quality of life. Newer oral regimens for multidrug-resistant TB are shorter and more effective than traditional regimens. New antibiotics under development may help overcome remaining safety and tolerability issues, while novel advanced therapeutics and precision medicine offer hope to those failing treatment. Emerging diagnostics include rapid DST for second-line drugs, but a paradigm shift is needed to ensure novel DSTs become available as new drugs are introduced. Person-centered research is urgently needed to accelerate the response to DR-TB amidst the global threat of antimicrobial resistance, yet global investment in TB prevention and care currently falls short of need. A holistic approach to interventions to improve DR-TB prevention and care is needed, encompassing all health system components and their interactions, including a One Health approach and consideration of the wider determinants of health.Keywords
Funding Information
- World Health Organization
This publication has 149 references indexed in Scilit:
- Role of therapeutic drug monitoring in the treatment of multi-drug resistant tuberculosisJournal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2024
- Epidemiology of extensively drug-resistant tuberculosis among patients with multidrug-resistant tuberculosis: A systematic review and meta-analysisInternational Journal of Infectious Diseases, 2023
- Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacinCochrane Database of Systematic Reviews, 2022
- Drug resistant TB – latest developments in epidemiology, diagnostics and managementInternational Journal of Infectious Diseases, 2022
- In linezolid underexposure, pharmacogenetics matters: The role of CYP3A5Biomedicine & Pharmacotherapy, 2021
- Nanomedicines towards targeting intracellular Mtb for the treatment of tuberculosisJournal of Interdisciplinary Nanomedicine, 2019
- New active formulations against M. tuberculosis: Bedaquiline encapsulation in lipid nanoparticles and chitosan nanocapsulesChemical Engineering Journal, 2018
- Quasi-experimental study designs series—paper 1: introduction: two historical lineagesJournal of Clinical Epidemiology, 2017
- Whole genome sequencing for M/XDR tuberculosis surveillance and for resistance testingClinical Microbiology and Infection, 2017
- Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: a systematic review and meta-analysisInternational Journal of Infectious Diseases, 2011